Hematological oncology

CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA.

L. Nayak, F.M. Iwamoto, A.J. Ferreri, A. Santoro, S. Singer, C. Batlevi, T. Batchelor, J. Rubenstein, P. Johnston, R. Ramchandren, C. Soussain, J. Drappatz, K. Becker, M. Witzens-Harig, G. Illerhaus, A. Herrera, A. Masood, M. Shipp

Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL.

Hematological oncology

J.L. Rubenstein, J. Hwang, G. Mannis

On point in primary CNS lymphoma.

Hematological oncology

Tsang M, Cleveland J, Rubenstein JL

IDENTIFICATION OF GENOMIC BIOMARKERS OF DISEASE PROGRESSION AND SURVIVAL IN NEWLY-DIAGNOSED PRIMARY CNS LYMPHOMA.

Hematological oncology

S. Mo, H. Geng, A. Ballapuram, L. Chen, M. Lu, W. P. Devine, K. W. Wen, D. Solomon, J. Rubenstein

BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models.

Hematological oncology

J. Ma, M. Lu, L. Chen, H. Geng, A. Kumar, M. Noviski, R. Rountree, C. Guiducci, J. Rubenstein

Search form

You are here

CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA.

Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL.

On point in primary CNS lymphoma.

IDENTIFICATION OF GENOMIC BIOMARKERS OF DISEASE PROGRESSION AND SURVIVAL IN NEWLY-DIAGNOSED PRIMARY CNS LYMPHOMA.

BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models.